<DOC>
	<DOCNO>NCT00515866</DOCNO>
	<brief_summary>The purpose study identify safe tolerable dose drug KU-0059436 give combination gemcitabine chemotherapy treatment pancreatic cancer .</brief_summary>
	<brief_title>Study Assess Safety &amp; Tolerability PARP Inhibitor Combination With Gemcitabine Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma pancreas Locally advance metastatic unresectable disease No prior anti cancer chemotherapy , radiotherapy ( except palliative &gt; 4 week prior entry , endocrine immunotherapy use investigational agent ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Advanced pancreatic cancer</keyword>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
	<keyword>Advanced Solid Tumours</keyword>
</DOC>